

友芝友生物製藥

## Wuhan YZY Biopharma Co., Ltd. 武漢友芝友生物製藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(在中華人民共和國註冊成立之股份有限公司)

(Stock Code 股份編號: 2496)

28 February 2024

Dear registered shareholder(s),

## Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Wuhan YZY Biopharma Co., Ltd. (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which means any documents issued or to be issued by the Company, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at <a href="https://www.hyzybio.com">www.yzybio.com</a> and the HKEXnews website at <a href="https://www.hkexnews.hk">www.hkexnews.hk</a> in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications (Note), the Company recommends you to provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong share registrar (the "Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send the Actionable Corporate Communications in printed form in the future.

If you want to receive the Corporate Communications in printed form, please complete the enclosed Reply Form and send it to the Share Registrar or send an email to YZYBIO.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the Share Registrar at +86 27-82668988-8802 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

By order of the board

Wuhan YZY Biopharma Co., Ltd. Dr. Zhou Pengfei

Chairman of the Board, Executive Director and Chief Executive Officer

Note: Actionable Corporate Communications refer to any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holders.

各位登記股東:

## 以電子方式發佈公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化制度及以電子方式發佈公司通訊規定下香港聯合交易所有限公司證券上市規則(「**上市規則**」)第 2.07A 條,武漢友芝友生物製藥股份有限公司(「**公司**」)謹此通知 閣下,公司已採用以電子方式發佈公司通訊(「**公司通訊**」)之安排,該公司通訊是指公司發佈或將要發佈的任何文件,包括但不限於(a) 董事報告、年度帳目以及審計報告副本及其財務摘要報告(如適用); (b) 中期報告及其中期報告摘要(如適用); (c) 會議通知; (d) 上市文件; (e) 通函; 和 (f) 委任表格。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 www.yzybio.com 和披露易網站 www.hkexnews.hk 上提供,以代替印刷本。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊<sup>(確定)</sup>,公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者,閣下也可以簽署回條並交回公司的香港股份過戶登記處(「**股份過戶處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

## 如果公司沒有收到 閣下的有效電子郵件地址,直至股份過戶處收到 閣下有效的電子郵件地址前,本公司將於日後以印刷本形式發送可供採取行動的公司通訊。

若 閣下希望收取公司通訊之印刷版,請填妥背頁之回條並交回股份過戶處,或發送電子郵件至 YZYBIO.ecom@computershare.com.hk, 並註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。 請注意,收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一年內有效,此後將過期。

如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午9時正至下午6時正(香港時間)其間致電股份過戶處+8627-82668988-8802查詢。

承董事會命 武漢友芝友生物製藥股份有限公司 董事長、執行董事兼首席執行官 Zhou Pengfei 博士

REPLY FORM	回條
------------	----

To: Computershare Hong Kong Investor Services Limited (the "Share Registrar")

17M Floor, Hopewell Centre

183 Queen's Road East, Wanchai, Hong Kong

(Please choose ONLY ONE of the options below)

香港中央證券登記有限公司 (「股份過戶處」) 致:

> 香港灣仔皇后大道東 183 號 合和中心 17M 樓

(請從以下選項中**只選擇其中一項**)

Personalized QR Code 專屬二維碼

Option 1: Provide your email address for receipt of future Actionable Corporate Communications (Note 3) of the Company via electronic dissemination by scanning your personalized QR code

選項1: 掃瞄 閣下專屬二維碼提供 閣下之電子郵件地址,以接收公司通過電子方式發 佈可供採取行動的未來公司通訊<sup>(附註3)</sup>

> You are **NOT required** to return this Reply Form if you choose "Option 1". 如選擇了「選項1」, 閣下無須交回本回條。

Ontion 2: I/we hereby	nrovide my/o	ur email add	ress in writing	for receipt of futu	re Actionable Corno	orate Communications <sup>(Note 3)</sup> of the following	listed
company vi	a electronic di	ssemination		•	•	電子方式發佈可供採取行動的公司通訊 <sup>/開生3</sup>	
Name of Securities holder(s) 證券持有人姓名: Name of the listed company 上市公司名稱: Wuhan YZY Biopharma Co., Ltd. 武漢友芝友生物製藥股份有限公司							
Email address 電郵地址: (Not	e 3 / 附註 3)						
		•.	•	unications* in prin		rk "✓" in the below box if applicable)	

			-
<u> </u>		form (Please mark "✓" in the below box if applicable	e)
選項3: 本人/吾等現要求收取公司通訊*!	<b>印刷版</b> (如適用,請在以下方格內劃上「	✓」號)	
receive future Corporate Communications* in 收取未來公司通訊*的印刷本,並已知悉本打	printed copy and noted that this instruction is valid 指示由收取指示日期起計一年內有效。 <sup>(附註 5)</sup>	only for one year starting from the receipt date of instruction.	Note 5)
☐ Printed English version 英文印刷本	☐ Printed Chinese version 中文印刷本	Printed English and Chinese versions 中、英文印刷本	:
Signature(s): (Note 1)	Contact number:	Date:	

簽名: (附註1)

see complete all your details clearly. If your shares are held in joint names, this Reply Form shall be deemed to be submitted by the joint registered holder whose name first appears on the register of members for and on behalf of all the joint registered holders. 請清楚類妥 閱下之所有資料。如屬聯名股東,則本回緣應被視為由於股東名冊內排名首位姓名的聯名登記股東代表所有聯名登記股東提交。

聯絡電話號碼:

明用是外来 南(この下来で・海中の東京 1974年後後後後の日本版本名刊刊刊日日に北石印象日上東京東京 1974年日上東京東京 Any Reply Form with no signature or otherwise incorrectly completed will be void. 任何回路若未有業者後在其他方面資富不正確。 別談會作権。 Ut the Company does not receive a functional amail address in your reply, you will be unable to receive notifications regarding the publication of Corporate Communications\*. Actionable Corporate Communications refer to any corporate ommunication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.
如公司沒有收到 周下的有效電子郵件地址, 周下將無法收到有關發佈公司通訊\*的通知。可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered. 如 関下通過二線碼、電郵、回條及或其他方式提供多於一個的電子郵件地址,只有 関下最後提供的電子郵件地址將會被用於登記。

uctounts togener with a copy of measurest report and the copy of the copy

PERSONAL INFORMATION COLLECTION STATEMENT

- "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
  本聲明中所指的「側人資料」與香港法門第 486 章 (個人資料 私題) 條例》(「《私題條例》」「「私題條例》」の「個人資料」的涵義相同。
  Your Personal Data provided in this Reply Form will be used in onenection with, including but not limited to, the Company's electronic dissemination of Corporate Communications\* and to liaise with you on other matters relating to your holdings in the Company, Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.
  関下食本回橡形提供的技术及演要来。
  Your Personal Data my be decised or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.

  You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Hory, Hopes Applications of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Hory, Hopes Applications of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Hory, Hopes Applications of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Hory, Hopes Applications of the PDPO. Any such request for access to and/or correction of your Person

 $\mathcal{Y}_{n}$ 

Mailing Label 郵寄標籤 Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼:37

Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

日期:

當 閣下寄回此回條時·請將郵寄標籤剪貼於信封上。 如在本港投寄 · 閣下無需支付郵費或貼上郵票。